The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients
source: pixabay.com

The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients

As reported in BioSpace, the FDA shocked Mesoblast executives, a stem-cell research company, when this October, they rejected the Biologics License Application (BLA) for the drug Ryoncil, meant to treat…

Continue Reading The FDA Rejects New Drug for SR-aGVHD, Shocking Scientists and Patients
Massachusetts General Cancer Center Receives the First Incyte Ingenuity Award for GvHD
source: pixabay.com

Massachusetts General Cancer Center Receives the First Incyte Ingenuity Award for GvHD

The global biopharmaceutical company Incyte recently announced the first-ever recipient of its Incyte Ingenuity Award, which will be the Massachusetts General Cancer Center (MGCC). The purpose of this award is…

Continue Reading Massachusetts General Cancer Center Receives the First Incyte Ingenuity Award for GvHD
COVID-19 Patients Were Removed From Ventilators Within Ten Days After Two Infusions of Ryoncil
source: pixabay.com

COVID-19 Patients Were Removed From Ventilators Within Ten Days After Two Infusions of Ryoncil

  A recent article in Biospace reported an 83% survival rate for COVID-19 patients after two infusions of the experimental drug Ryoncil, developed by Mesoblast Ltd. The patients who were…

Continue Reading COVID-19 Patients Were Removed From Ventilators Within Ten Days After Two Infusions of Ryoncil
Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease
source: pixabay.com

Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease

Chronic granulomatous disease (CGD) is a rare form of immunodeficiency. The most common form of this disease is X-linked chronic granulomatous disease (X-CGD) which is caused by a mutated CYBB gene. This…

Continue Reading Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease

Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…

Continue Reading Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

Interim Data for Phase 3 Graft-versus-Host Disease Trial Looks Promising

According to a story from PR Newswire, the specialty pharmaceutical company Mallinckrodt plc recently announced the release of interim data from the company's Phase 3 clinical trial. This trial is…

Continue Reading Interim Data for Phase 3 Graft-versus-Host Disease Trial Looks Promising
Researchers Discover Causes of Graft-Verus-Host-Disease
Source: Pixabay

Researchers Discover Causes of Graft-Verus-Host-Disease

Research into graft-versus-host-disease (GVHD), a condition that can occur after bone marrow transplants, has yielded promising results. A study, reported by BrightSurf, found that a particular group of microRNA molecules involved…

Continue Reading Researchers Discover Causes of Graft-Verus-Host-Disease
Close Menu